Theriva Biologics Q2 2026: Cash $11.3M, VIRAGE2 first patients dosed

Theriva Biologics, Inc.

Cash and cash equivalents $11.3M as of June 30, 2026; runway into Q1 2027.
G&A expenses down 82% YoY to $2.0M from $11.2M; prior-year $9.2M contingent consideration adjustment.
R&D expenses down 35% to $1.3M from $2.0M; H1 2026 net loss $5.3M.
First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment completion expected H2 2026.
Proposed Phase 2/3 retinoblastoma trial design completed; FDA discussion planned Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.